BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32352922)

  • 21. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
    Zhao C; Ma SPZCY
    J BUON; 2019; 24(3):1150-1166. PubMed ID: 31424674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
    Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
    J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial).
    Zhu HD; Li X; Sun JH; Zhu X; Liu ZY; Li HL; Lu J; Yan ZP; Shao GL; He XF; Chao M; Lu LG; Zhong BY; Li R; Zhang Q; Teng GJ
    Cardiovasc Intervent Radiol; 2024 Mar; 47(3):325-336. PubMed ID: 38413420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.
    Maschke SK; Werncke T; Klöckner R; Rodt T; Renne J; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
    Abdom Radiol (NY); 2018 May; 43(5):1245-1253. PubMed ID: 28840307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety.
    Ballı HT; Aikimbaev K
    Diagn Interv Radiol; 2020 Sep; 26(5):482-487. PubMed ID: 32815520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres
    Zhang X; Lin X; Qiu H; Peng Z
    J Clin Lab Anal; 2019 Oct; 33(8):e22975. PubMed ID: 31328832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
    Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR
    Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
    Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.
    Zhao G; Liu S; Chen S; Ren Z; Li C; Bian J; Wu J; Zhou J; Zhang Y
    Drug Deliv; 2021 Dec; 28(1):1356-1362. PubMed ID: 34180755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries.
    Lokken RP; Fidelman N; Kolli KP; Kerlan RK
    J Vasc Interv Radiol; 2016 Nov; 27(11):1698-1704. PubMed ID: 27397617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiological characteristics of hepatocellular carcinoma that achieved complete response after chemoembolization with drug-eluting beads for liver transplantation planning.
    Valle LGM; Cunha MJS; Schmid BP; Falsarella PM; Rezende MB; Felga GEG; Ogawa RE; Garcia RG; Affonso BB; Nasser F; Galastri FL
    Einstein (Sao Paulo); 2023; 21():eAO0307. PubMed ID: 37909650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
    Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
    Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
    Wen P; Chen SD; Wang JR; Zeng YH
    Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.